Please take a minute and help us choose a new logo for the Stop TB Partnership’s Working Group on New Drugs (WGND).

Since our inception in 2001, the WGND has evolved and expanded greatly. Through our membership and activities, we have been able to contribute to the critical collaborations and partnerships that have led to a coordinated portfolio of promising new compounds for the first time in 20 years. Some of these compounds have the potential to become the cornerstone drugs of TB control and contribute to the elimination of TB in the future.

Notice from the Stop TB Partnership:

We are writing to encourage you to sign the Call to Action on Childhood TB.

The call was an outcome of an international meeting organized jointly by the European Centre for Disease Prevention and Control (ECDC) and the Stop TB Partnership’s Childhood TB Subgroup in March.

The meeting was attended by a wide range of participants, including researchers, paediatricians, community representatives, civil society organizations, and ECDC and WHO staff. The objectives of the meeting were to:

Dr. Mark Cotton is Director of Children’s Infectious Diseases Clinical Research Unit (KID-CRU) at University of Stellenbosch in Cape Town, South Africa. Pediatric TB has emerged as a broad priority only in more recent years, though the University of Stellenbosch / Tygerberg Hospital team has been focusing on it for more than 20 years.

This is part two of our interview with him.

Dr. Peter Andersen, the Vice President of Vaccine Research and Development at Statens Serum Institut (SSI) and TBVI partner, has been awarded the prestigious Novo Nordisk prize for his work in TB vaccine development. The WGND interviewed Dr.